The Federal Circuit has ruled that a Novartis patent is valid despite an error of reasoning from a district court.
Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.
The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.
A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.
Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.